# A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558

> **NCT05685719** · PHASE1 · COMPLETED · sponsor: **Zhejiang ACEA Pharmaceutical Co. Ltd.** · enrollment: 37 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** STI-1558
- **DRUG:** Itraconazole
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT05685719
- **Lead sponsor:** Zhejiang ACEA Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-04
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-11-03
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2023-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05685719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05685719, "A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05685719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*